Market revenue in 2023 | USD 15.9 million |
Market revenue in 2030 | USD 80.2 million |
Growth rate | 26% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.76% in 2023. Horizon Databook has segmented the Italy peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
The healthcare system in Italy is well-established, which is contributing to growth of Italy’s peptide drug conjugates market. The country provides universal healthcare coverage benefits to its citizens, but the Italian government adopts special measures to ensure healthcare accessibility to vulnerable groups, such as individuals suffering from various target diseases, including cancer, cardiovascular diseases, metabolic disorders, & respiratory diseases.
Moreover, market growth can be attributed to the presence of local players and increasing research activities in the field of peptide-based drug development in the country. Moreover, increasing R&D investments and continuous research by scientists have boosted the demand for novel therapeutics in Italy.
In addition, ongoing strategic initiatives undertaken by regional players to provide innovative solutions are expected to support market growth in the country. However, in May 2022, an announcement from Novartis reverberated across the peptide drug conjugate market, as the company made the decision to temporarily halt production at its Ivrea, Italy, and Millburn, New Jersey facilities.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy peptide drug conjugates market , including forecasts for subscribers. This country databook contains high-level insights into Italy peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account